MedPath

Glyscend, Inc.

Glyscend, Inc. logo
🇺🇸United States
Ownership
Holding
Employees
1
Market Cap
-
Website
http://www.glyscend.com

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Phase 2
Completed
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2024-02-14
Last Posted Date
2025-01-23
Lead Sponsor
Glyscend, Inc.
Target Recruit Count
75
Registration Number
NCT06259981
Locations
🇺🇸

Tampa Bay Medical Research, Inc., Clearwater, Florida, United States

🇺🇸

Sensible Healthcare, LLC, Ocoee, Florida, United States

🇺🇸

Tandem Clinical Research, Marrero, Louisiana, United States

and more 2 locations

A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

Phase 2
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Placebo
First Posted Date
2022-07-28
Last Posted Date
2025-02-10
Lead Sponsor
Glyscend, Inc.
Target Recruit Count
51
Registration Number
NCT05478525
Locations
🇺🇸

ProSciento, Inc., Chula Vista, California, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.